Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity.
about
Application of dried blood spot sampling combined with LC-MS/MS for genotyping and phenotyping of CYP450 enzymes in healthy volunteers.Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanilPharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping.Association of genotypes of the CYP3A cluster with midazolam disposition in vivo.Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.Evaluation of single-point sampling strategies for the estimation of moclobemide exposure in depressive patients.Evaluation of limited sampling models for prediction of oral midazolam AUC for CYP3A phenotyping and drug interaction studies.Concentration effect relationship of CYP3A inhibition by ritonavir in humans.Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm.Limited sampling strategy in rats to predict the inhibited activities of hepatic CYP3A.Effects of tranexamic acid on coagulation indexes of patients undergoing heart valve replacement surgery under cardiopulmonary bypass.Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy.
P2860
Q33810432-6AE7C61D-3523-4D7B-9370-0DAA0EC6B21BQ35884179-5F36E2C0-BF63-45B5-8846-DA90067382D3Q36578060-C5E1DC1D-FCC8-486E-806B-CB85FADB3046Q36646017-9FEB8D14-B132-44A7-807A-74461EFE6F2CQ36922212-D8E1142F-7451-4E24-883C-6DADB67CD2FCQ37359687-873B09CD-FFAC-46F4-BBB8-909917052046Q43626046-014B4C81-172F-4D19-940A-F584692103B3Q43731280-60D51FA8-B1C4-481C-AC39-466E35CB903AQ44998438-12717247-1C36-48D4-8DEE-2822D8B75789Q45995116-6E3A2A18-6264-4AD6-8A13-BE193DD8C9C1Q46107342-1617258C-6069-49B7-9E2D-F64B5F4C7283Q46112124-B190D2D2-1F3F-4D64-8A33-6D9A2EFFAD82Q47382217-9F03C0C0-9A82-4219-8BC9-E5F6FB72FFD3Q47400081-6CBD0FD2-68B9-4B7A-A9BC-2B5FD59BF754Q48228997-EF5E1F67-B5D7-4DAA-8C60-2574A3089CB6
P2860
Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Limited sampling models for or ...... a biomarker of CYP3A activity.
@en
Limited sampling models for or ...... a biomarker of CYP3A activity.
@nl
type
label
Limited sampling models for or ...... a biomarker of CYP3A activity.
@en
Limited sampling models for or ...... a biomarker of CYP3A activity.
@nl
prefLabel
Limited sampling models for or ...... a biomarker of CYP3A activity.
@en
Limited sampling models for or ...... a biomarker of CYP3A activity.
@nl
P2093
P2860
P356
P1476
Limited sampling models for or ...... a biomarker of CYP3A activity.
@en
P2093
Anne N Nafziger
Joseph S Bertino
Lois S Lee
P2860
P304
P356
10.1177/0091270005283466
P577
2006-02-01T00:00:00Z